Gilead says on­ly Te­va can mar­ket Tru­va­da gener­ic; Den­ver nar­row­ly votes to de­crim­i­nal­ize "mag­ic mush­rooms"

7 years ago
News Briefing

Push­ing hard for block­buster re­turns, No­var­tis finds PhI­II da­ta to as­sert Mayzent boosts cog­ni­tive pow­ers in MS ...

7 years ago
R&D

Pre­clin­i­cal da­ta on MD An­der­son Can­cer Cen­ter-de­vel­oped drug of­fers hope for Im­bru­vi­ca-re­sis­tant man­tle cell lym­phoma ...

7 years ago
R&D

Once the cen­ter of a pub­lic storm of anger over de­nied drug, Chimerix now can’t even re­cruit pa­tients for their ...

7 years ago
R&D

An­oth­er PhI­II #fail for Bris­tol-My­ers’ star drug rais­es fresh ques­tions about their R&D strat­e­gy as Mer­ck surges ...

7 years ago
R&D

Four biotechs haul in $303M+ from a fresh burst of IPOs

7 years ago
Financing

New study spot­lights a link be­tween block­buster SGLT2 drugs and po­ten­tial­ly lethal gan­grene

7 years ago
R&D

Take­da inks a pair of sales to No­var­tis and J&J for up to $5.7B, hand­ing over 485 staffers

7 years ago
Pharma

List prices in drug ads on TV com­ing as CMS fi­nal­izes rule

7 years ago
Pharma

BioN­Tech nabs PhI an­ti­body and a new US base out of bank­rupt­cy; Pfiz­er wins con­di­tion­al drug OK

7 years ago
News Briefing

Work with Flori­da on its drug im­port pro­gram, Trump tells Azar — re­port

7 years ago
Pharma

Look­ing to top­ple Pfiz­er's Pre­vnar 13 dy­nasty, Mer­ck claims an­oth­er win for its 'break­through' pneu­mo­coc­cal con­ju­gate ...

7 years ago
R&D

Sarep­ta goes back to the gene ther­a­py well at Na­tion­wide Chil­dren’s for its lat­est mus­cle-wast­ing pro­gram

7 years ago
Cell/Gene Tx

Till­man Gern­gross is­n't out to im­press you with biobucks, but here are 3 part­ner deals that should

7 years ago
People
Pharma

Pfiz­er buys a rare dis­ease biotech for $340M-plus, putting them on a path to com­pete with Bio­Marin

7 years ago
R&D
Pharma

Gilead wa­gers $109M — cash — that this biotech can il­lu­mi­nate a drug dis­cov­ery path point­ed straight in­to the ...

7 years ago
R&D

As­traZeneca’s $7B bet on Dai­ichi Sankyo’s an­ti­body drug con­ju­gate pays off with piv­otal da­ta to back their ...

7 years ago
R&D

Re­gen­eron’s star bis­pe­cif­ic is linked to 2 deaths in a small study — which was no help for its Q1 call

7 years ago
R&D

Brent Saun­ders has a mes­sage for Al­ler­gan in­vestors to­day: He feels your pain

7 years ago
People

Bel­gium's liv­er-fo­cused stem cell ther­a­py de­vel­op­er Promethera rais­es $44M+ in lat­est round

7 years ago
Financing

Con­fo Ther­a­peu­tics rais­es €30 mil­lion; Waylivra re­ceives ap­proval from EU; end­point met for Mer­ck­'s Bel­som­ra in ...

7 years ago
News Briefing

$250M As­traZeneca spin­off preps leap in­to 3-way bat­tle with ti­tans for a rare dis­ease mar­ket that spans the globe

7 years ago
R&D

Rat­tle and hum: Roche, PTC post up­date on their SMA drug as a shak­en Bio­gen faces yet an­oth­er fran­chise buster

7 years ago
R&D
Pharma

Al­ler­gan chief Saun­ders takes a painful $2.5B hit on an ug­ly PhI­II flop

7 years ago
People
R&D
First page Previous page 951952953954955956957 Next page Last page
A service from the Financial Times